⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALNY News
Alnylam Pharmaceuticals, Inc.
Alnylam présente de nouvelles données lors du congrès de l’ESC 2026, qui confirment l’efficacité de l’inhibition de la TTR par ARNi chez les populations de patients atteints d’ATTR-CM et dans différents contextes thérapeutiques
businesswire.com
ALNY
Alnylam präsentiert auf dem ESC Congress 2026 neue Daten, die die Wirksamkeit des RNAi-basierten TTR-Silencing bei verschiedenen ATTR-CM-Patientengruppen und in verschiedenen Behandlungsumgebungen belegen
businesswire.com
ALNY
Alnylam presenta nuevos datos en el Congreso 2026 de la ESC que refuerzan la eficacia en el silenciamiento de la transtiretina mediante interferencia de ARN en poblaciones de pacientes y entornos de tratamiento de miocardiopatía amiloide por trans...
businesswire.com
ALNY
Alnylam presenta nuovi dati al Congresso ESC 2026, rafforzando l'efficacia del silenziamento della transtiretina (TTR) basato sulla tecnologia RNAi nelle popolazioni di pazienti affetti da ATTR-CM e nei diversi contesti terapeutici
businesswire.com
ALNY
Alnylam presenteert nieuwe gegevens op het ESC-congres 2026 en legt de nadruk op de effectiviteit van RNAi-gebaseerde TTR-silencing bij verschillende ATTR-CM-patiëntengroepen
businesswire.com
ALNY
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
businesswire.com
ALNY
ALNY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alnylam Pharmaceuticals, Inc.
globenewswire.com
ALNY
Global RNAi Technology Market is Expected to Showcase Significant Growth at a CAGR of ~14% by 2034 | DelveInsight
globenewswire.com
BNTX
MRNA
DVAX
ALNY
BIIB
IONS
ARCT
VRTX
PFE
SGMO
AZN
CAT
TMO
LH
Global Huntington's Disease Treatment Market 2026-2031 - Advancements in Novel Therapeutics to Drive Growth
globenewswire.com
PFE
TEVA
NBIX
ALNY
IONS
NVS
QURE
SANG
PTC
WVE
Dravet Syndrome Market Trends Indicate Sustained Growth During the Forecast Period (2026–2036), Driven by Novel Treatment Approaches | DelveInsight
globenewswire.com
BIIB
HRMY
XNCR
AZN
LLY
PFE
REGN
NVS
TSLA
TAK
GSK
JNJ
UCB
BHF
PRAX
XENE
AQST
TNDM
INCY
MRK
ABBV
BMY
AMGN
GILD
VRTX
CRSP
EDIT
NTLA
SRPT
ALNY
EXAS
TEVA
AXSM
CYTK
INSM
KODK
LPCN
MNKD
NBIX
NCLH
ONCY
ORIC
PBYI
PEGA
PLRX
PRGS
QGEN
RGNX
ROST
RYAAY
SNOW
SWKS
SYK
TGT
TRMB
TXG
ULTA
VRSK
WDC
WVE
XOM
ZBRA
ZNTL
ZTS
STOK
IONS
MOMO
BBAR
CTXR
MBIO
GNS
NEON
OVID
BHVN